Wells Fargo & Company Eli Lilly & CO Call Options Transaction History

Wells Fargo & Company

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 15, 2023	SELL	$350.74 - $468.98 $1.09 Million - $1.45 Million	-3,100 Reduced 79.49%	800 $375,000
Q1 2023 May 12, 2023	BUY	$310.63 - $364.82 $1.03 Million - $1.2 Million	3,300 Added 550.0%	3,900 $1.34 Million
Q4 2022 Feb 13, 2023	SELL	$321.55 - $374.67 $6.24 Million - $7.27 Million	-19,400 Reduced 97.0%	600 $219,000
Q3 2022 Nov 14, 2022	BUY	$296.48 - $337.87 $5.93 Million - $6.76 Million	20,000 New	20,000 $6.47 Million
Q4 2021 Feb 14, 2022	BUY	$224.85 - $279.04 $4.5 Million - $5.58 Million	20,000 New	20,000 $5.52 Million

3,719

738M

7.09M

7.24M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $860B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.